Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Eli Lilly stock plunges. To find out what lies ahead for Eli Lilly in this increasingly competitive environment, visit CDS.

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Key Takeaways More than 1 in 10 Americans has tried a GLP-1 drug50- to 64-year-olds report the most useSide effects like nausea and diarrhea are common but mild FRIDAY, Aug. 8, 2025 (HealthDay News) — ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

U.S. stocks drifted to a mixed finish on Thursday as President Donald Trump's tariffs taking effect on dozens of countries ...

U.S. stocks drifted to a mixed finish as President Donald Trump’s tariffs on dozens of countries had only a muted effect on ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...